Straits Times Index
3,323.20 -6.89 (-0.21%) S&P 500
5,306.04 +1.32 (+0.02%) Dow
38,852.86 -216.74 (-0.55%) Nasdaq
17,019.88 +99.08 (+0.59%) Bitcoin USD
67,774.30 -456.90 (-0.67%) CMC Crypto 200
1,461.75 -22.94 (-1.55%)
OLMA Jul 2024 7.500 call
| Previous close | 3.0000 |
| Open | 3.0000 |
| Bid | 0.0000 |
| Ask | 0.0000 |
| Strike | 7.50 |
| Expiry date | 2024-07-19 |
| Day's range | 3.0000 - 3.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | N/A |
GlobeNewswireOlema Oncology to Participate in Upcoming Investor Conferences in June
SAN FRANCISCO, May 28, 2024 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference Date: Wednesday, June 5, 2024, at 2:00 p.m. ET Location: Marriott Marquis in New York, NY
Simply Wall St.Olema Pharmaceuticals (NASDAQ:OLMA) Is In A Good Position To Deliver On Growth Plans
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
- GlobeNewswire
Olema Oncology Announces Promising New Data for Palazestrant in Combination with Ribociclib Presented at the 2024 ESMO Breast Cancer Congress
Across 50 treated patients, palazestrant (OP-1250) in combination with ribociclib was well tolerated with no new safety signals or increased toxicity and no clinically meaningful impact on drug exposure of either therapy85% clinical benefit rate (CBR) observed to date across all CBR-eligible patients supports promising preliminary efficacy profile of the palazestrant-ribociclib combination Olema will host an investor conference call today at 8:00 a.m. ET SAN FRANCISCO, May 15, 2024 (GLOBE NEWSWI
